JP6615007B2 - Oral composition - Google Patents

Description

  The present invention relates to an oral composition.

  For oral compositions, it is known that a combination of pyrrolidone carboxylic acid and various components is effective in order to enhance the medicinal effect or feeling of use (for example, Patent Documents 1 and 2).

International Publication No. 2014/073490 International Publication No. 2014/157547

  ε-aminocaproic acid is known as an anti-inflammatory agent. However, oral compositions containing ε-aminocaproic acid sometimes discolored during storage, resulting in poor formulation stability. An object of the present invention is to provide a composition for oral cavity which has a good anti-inflammatory effect and is prevented from being discolored during storage, that is, having discoloration stability.

That is, the present invention provides the following.
[1] An oral composition containing (A) pyrrolidonecarboxylic acid and / or a salt thereof, (B) ε-aminocaproic acid and / or a salt thereof, and (C) a vitamin and / or a terpene.
[2] The composition for oral cavity according to [1], wherein the vitamin is one or more vitamins containing at least vitamin E or vitamin B2.
[3] The oral composition according to [1] or [2], wherein the terpene is one or more terpenes containing at least limonene and / or menthol.

  ADVANTAGE OF THE INVENTION According to this invention, it has the favorable anti-inflammatory effect and can provide the composition for oral cavity excellent in the discoloration stability.

  The composition of this invention contains the (A)-(C) component demonstrated below.

  The component (A) is pyrrolidone carboxylic acid and / or a salt thereof. The pyrrolidone carboxylic acid may be naturally derived or synthesized. A method for synthesizing pyrrolidone carboxylic acid is not particularly limited, and examples thereof include a method of dehydrating and producing glutamic acid extracted from raw materials such as seaweed, wheat flour, and sugarcane.

  The salt in the pyrrolidone carboxylate is not particularly limited as long as it is a pharmacologically acceptable salt. Examples of pharmacologically acceptable salts include acid addition salts, base addition salts, and amino acid salts. Specific examples thereof include inorganic acid salts such as hydrochloride, hydrobromide, sulfate, hydroiodide, nitrate, phosphate; citrate, oxalate, acetate, formate, propion Acid salt, benzoate salt, trifluoroacetate salt, maleate salt, tartrate salt, methanesulfonate salt, benzenesulfonate salt, paratoluenesulfonate salt, etc .; sodium salt, potassium salt, aluminum salt, ammonium salt Inorganic base salts such as salts; organic base salts such as triethylammonium salt, triethanolammonium salt, pyridinium salt, diisopropylammonium salt; amino acid salts such as lysine salt, arginine salt, histidine salt, aspartate, glutamate, etc. . Among these salts, water-soluble salts are preferable, inorganic base salts are preferable, and alkali metal salts such as sodium salts and potassium salts are more preferable.

  The component (A) may be pyrrolidone carboxylic acid, at least one selected from pyrrolidone carboxylates, or a combination thereof.

  (A) 0.1 mass% or more is preferable, as for content of a component, 0.5 mass% or more is more preferable, and the mass% or more is further more preferable. Thereby, the effects of the present invention such as discoloration stability can be sufficiently exhibited. The upper limit is preferably 10% by mass or less, and more preferably 5% by mass or less. Thereby, the fall of formulation stability can be prevented. Accordingly, the content is preferably 0.1 to 10% by mass, and more preferably 0.5 to 5% by mass from the viewpoint of improving the effect.

  The component (B) is ε-aminocaproic acid and / or a salt thereof. ε-aminocaproic acid may be naturally derived or synthesized. Examples of the salt in ε-aminocaproate include the same salts as the salt of component (A).

  Component (B) may be ε-aminocaproic acid, may be at least one selected from ε-aminocaproic acid salts, or a combination thereof.

  (B) 0.002 mass% or more is preferable and, as for content of a component, 0.005 mass% or more is more preferable. Thereby, an anti-inflammatory effect can fully be exhibited. The upper limit is preferably 1% by mass or less, and more preferably 0.5% by mass or less. Thereby, the fall of formulation stability can be prevented. Accordingly, the content is preferably 0.002 to 1% by mass, and more preferably 0.005 to 0.5% by mass from the viewpoint of improving the anti-inflammatory effect.

  Component (C) is a vitamin and / or terpene.

  Examples of vitamins include fat-soluble vitamins A, D, E, and K; and water-soluble vitamins such as vitamins B and C. Examples of vitamin A include retinol and retinol derivatives. Examples of vitamin B include vitamin B1 such as thiamine and thiamine derivatives (eg thiamine nitrate); vitamin B2 such as riboflavin and riboflavin derivatives (eg riboflavin sodium phosphate); vitamin B3 such as niacin and niacin derivatives; pantothenic acid, Vitamin B5 such as nicotinic acid or derivatives thereof (eg, calcium pantothenate, nicotinamide); vitamin B6 such as pyridoxal, pyridoxamine, pyridoxine, derivatives thereof (eg, pyridoxine hydrochloride); vitamin B7 such as biotin; folic acid, etc. And vitamin B12 such as cyanocobalamin and hydroxocobalamin. Examples of vitamin C include ascorbic acid and its derivatives. Examples of vitamin E include tocopherol, tocotrienol, and derivatives thereof (eg, tocopherol acetate). Examples of vitamin K include naphthoquinone derivatives (eg, phylloquinone, menaquinone). Of these, fat-soluble vitamins are preferred, vitamins B2, E or combinations thereof are more preferred, and tocopherol acetate, riboflavin or combinations thereof are even more preferred.

Terpenes are generally chain and cyclic hydrocarbons having a structure represented by the molecular formula (C ₅ H ₈ ) _n (isoprene structure; 2-methylbutane skeleton), and derivatives thereof (eg, aldehydes, ketones, alcohols, esters). ). Examples of terpenes include hemiterpene C ₅ H ₈ , monoterpene C ₁₀ H ₁₆ , sesquiterpene C ₁₅ H ₂₄ , diterpene C ₂₀ H ₃₂ , polyterpene (C ₅ H ₈ ) _n ; acyclic terpene, monocyclic (Monocyclic) terpenes, bicyclic terpenes. Examples of hemiterpenes include alcohol derivatives such as prenol; carboxylic acid derivatives such as tiglic acid, angelic acid, senecioic acid, and isovaleric acid. Monoterpenes include, for example, chain monoterpenes such as citronellol, geraniol, nerol, linalool, citral, neral, myrsenol, myrcene, osimene, cosmen; Aldehyde derivatives such as cyclic monoterpene alcohols such as terpineol and menthol, neral and geranial; furanoid derivatives such as perylene and rosefuran; and carboxylic acid derivatives such as geranilic acid. Examples of sesquiterpenes include farnesol, carotol, nerolidol, and eudarene. Examples of diterpenes include geranylgeraniol, phytol, abietic acid, pimaradine, daphnetoxin, taxol, and pimaric acid. Among these, monoterpenes are preferable, cyclic monoterpenes are more preferable, and menthol, limonene, or a combination thereof is more preferable.

  Terpenes and vitamins may be naturally derived or synthesized. You may mix | blend 1 type (s) or 2 or more types. Terpenes are usually extracted from raw materials such as essential oils and natural resins.

  Component (C) may be at least one terpene, at least one vitamin, or a combination thereof.

  (C) 0.01 mass% or more is preferable and, as for content of a component, 0.1 mass% or more is more preferable. Thereby, the effects of the present invention such as discoloration stability can be sufficiently exhibited. The upper limit is preferably 2% by mass or less, and more preferably 1% by mass or less. Thereby, the fall of formulation stability can be prevented. Therefore, 0.01-2 mass% is preferable, and from the point of an effect improvement, More preferably, it is 0.1-1 mass%.

  The ratio of the content of the component (A) to the content of the component (B) is preferably ((A) / (B)), 2 or more, and more preferably 6 or more. The upper limit is preferably 1500 or less, and more preferably 600 or less.

  The ratio ((A) + (B) / (C)) of the content of the component (A) to the content of the component (C) and the content of the component (B) is preferably 1.5 or more, 3 or more is more preferable. The upper limit is preferably 600 or less, more preferably 350 or less, and particularly preferably 100 or less.

  Although the dosage form and shape of the composition of this invention are not specifically limited, For example, liquid (solution, emulsion, suspension, etc.) and semi-solid (gel, cream, paste, etc.) are mentioned. Preferably, it is liquid or semi-solid, more preferably semi-solid.

  The composition of the present invention may be used for oral cavity, for example, dentifrice (toothpaste, liquid dentifrice, liquid dentifrice, powder dentifrice, etc.), mouthwash, tablet, granule, mouth freshener, oral application , Oral patch, chewing gum, tablet confectionery, candy, gummi, film, troche. Dentifrices and mouthwashes are preferred.

  The composition of the present invention may contain components (arbitrary components) other than the components (A) to (C) as necessary. Optional components are not particularly limited, but, for example, surfactants, abrasives, binders, thickeners, sweeteners, preservatives, fragrances, medicinal ingredients, colorants, brighteners, pH adjusters, water and other solvents Excipients. Although the specific example of an arbitrary component is shown below, the arbitrary component in this invention is not restrict | limited to these.

  Examples of the surfactant include N-acyl amino acid salts, α-olefin sulfonates, N-acyl sulfonates, alkyl sulfates, sulfates of glycerin fatty acid esters, polyoxyethylene alkyl ethers, Nonoxy surfactants such as polyoxyethylene-polyoxypropylene block copolymer, polyoxyethylene hydrogenated castor oil, polyoxyethylene ether of glycerin ester, sucrose fatty acid ester, alkylolamide, alkylbetaine amphoteric surfactant, Examples include betaine-type amphoteric surfactants such as imidazolinium betaine-based amphoteric surfactants and amphoteric surfactants such as amine oxide-based surfactants. These surfactants may be used alone or in combination of two or more.

  As the anionic surfactant, N-acylamino acid salts, α-olefin sulfonates, alkyl sulfates, and the like are preferable from the viewpoint of versatility. In terms of foamability and hard water resistance, examples include sodium lauroyl sarcosine, sodium α-olefin sulfonate having 10 to 16 carbon atoms as the alkyl chain length, and sodium lauryl sulfate.

  As the nonionic surfactant, for example, polyoxyethylene alkyl ether, polyoxyethylene hydrogenated castor oil, alkylolamide, sorbitan fatty acid ester and the like are preferable from the viewpoint of versatility. That is, for example, polyoxyethylene alkyl ether having an alkyl chain having a carbon chain length of 14 to 18, an average number of moles of added ethylene oxide of 15 to 30, and a polyoxyethylene cured castor having an average number of moles of added ethylene oxide of 20 to 100 Oil, alkylolamide having 12 to 14 carbon atoms as carbon chain length of alkyl chain, sorbitan fatty acid ester having 12 to 18 carbon atoms of fatty acid, 16 to 18 carbon atoms of fatty acid, and average number of moles of ethylene oxide added 10-40 polyoxyethylene sorbitan fatty acid ester is mentioned.

  As the amphoteric surfactant, a betaine-type amphoteric surfactant is preferable. Examples of the betaine amphoteric surfactant include lauryl betaine, stearyl betaine, lauryl dimethylaminoacetic acid betaine, stearyldimethylaminoacetic acid betaine, 2-alkyl-N-carboxymethyl-N-hydroxyethylimidazolinium betaine, N-lauroyl- N'-carboxymethyl-N'-hydroxyethylethylenediamine sodium, lauric acid amidopropyl betaine, coconut oil fatty acid amidopropyl betaine, and lauryl hydroxysulfobetaine. Among them, lauryldimethylaminoacetic acid betaine, coconut oil fatty acid amidopropyl betaine, 2-alkyl-N-carboxymethyl-N-hydroxyethylimidazolinium betaine and N-lauroyl-N′-carboxymethyl-N′-hydroxyethylethylenediamine sodium It is more preferable that it contains coconut oil fatty acid amidopropyl betaine.

  Examples of the abrasive include silica-based abrasives such as silicic anhydride, crystalline silica, amorphous silica, silica gel, aluminosilicate, zeolite, calcium hydrogen phosphate anhydrous, calcium hydrogen phosphate dihydrate, pyro Examples thereof include calcium phosphate, calcium carbonate, aluminum hydroxide, alumina, magnesium carbonate, tertiary magnesium phosphate, zirconium silicate, tertiary calcium phosphate, hydroxyapatite, quaternary calcium phosphate, and a synthetic resin abrasive.

  An abrasive | polishing agent may be single 1 type, and 2 or more types of combinations may be sufficient as it. When the abrasive is included, the content is preferably 2 to 40% by mass, and more preferably 5 to 20% by mass with respect to the entire composition.

  Examples of the binder include pullulan, gelatin, methyl cellulose, carboxymethyl cellulose and salts thereof (for example, sodium salt), hydroxyethyl cellulose and salt thereof (for example, sodium salt), hydroxypropyl cellulose and salt thereof (for example, sodium salt), hydroxypropyl Methyl cellulose and its salts (for example, sodium salt), carrageenan, sodium alginate, xanthan gum, sodium polyacrylate, gum arabic, guar gum, locust bean gum, polyvinyl alcohol, polyvinyl pyrrolidone, carboxyvinyl polymer and other organic binders, thickening silica And inorganic binders such as silicic anhydride. The binder may be used alone or in combination of two or more. When the binder is included, the content thereof is usually 0.01 to 15% by mass, preferably 0.01 to 13% by mass with respect to the entire composition. Content of an organic binder is 0.01-5 mass% normally with respect to the whole composition, Preferably it is 0.01-3 mass%. Content of an inorganic binder is 0.1-10 mass% normally with respect to the whole composition.

  Examples of the thickener include propylene glycol, butylene glycol, glycerin, sorbitol, polyethylene glycol and the like. When the thickener is included, the content thereof may be usually 1 to 50% by mass with respect to the entire composition. One type of thickener may be used alone, or two or more types may be used in combination.

  Examples of the sweetening agent include saccharin sodium, stevioside, neohesperidin hydrochalcone, glycyrrhizin, perilartin, p-methoxycinnamic aldehyde, thaumatin, palatinose, maltitol, xylitol, arabitol and the like. One sweetener may be used alone, or two or more sweeteners may be used in combination.

  Examples of the preservative include sodium benzoate, paraoxybenzoate ester, methyl paraben, ethyl paraben, butyl paraben, and ethylenediamine tetraacetate. One preservative may be used alone, or two or more may be used in combination.

  The form of the fragrance is not limited, and any of essential oil, extract, solid, and powder obtained by spray drying any of them may be used. A fragrance | flavor should just be except (C) component, and is not specifically limited.

  The medicinal component may be other than components (B) and (C), and examples thereof include the following components: bactericidal or antibacterial such as chlorohexidine, triclosan, isopropylmethylphenol, cetylpyridinium chloride, benzethonium chloride, and benzalkonium chloride Agents; anticalculus agents such as condensed phosphate and ethane hydroxydiphosphonate; anti-inflammatory agents other than component (B) such as glycyrrhizin dipotassium salt; coating agents such as hydroxyethylcellulose dimethyldiallylammonium chloride, dextranase, Enzyme agents such as mutanase; astringents such as allantoin chlorohydroxyaluminum, lysozyme chloride, glycyrrhetinic acid and salts thereof, sodium chloride and allantoin; antihypersensitive agents such as potassium nitrate and aluminum lactate; and sodium fluoride, Tsu potassium, ammonium fluoride, stannous fluoride, Aminfu' fluoride, sodium monofluorophosphate, potassium monofluorophosphate, sodium fluorosilicate, fluorine compounds such as silicon fluoride calcium. The medicinal component may be appropriately selected within a pharmaceutically acceptable range. When a fluorine compound is included, the content is preferably 50 to 3000 ppm as fluorine.

  Examples of the coloring agent include natural dyes such as safflower red pigment, gardenia yellow pigment, gardenia blue pigment, perilla pigment, red potato pigment, red cabbage pigment, carrot pigment, hibiscus pigment, cacao pigment, spirulina pigment, tamarind pigment, Legal pigments such as Red No. 3, Red No. 104, Red No. 105, Red No. 106, Yellow No. 4, Yellow No. 5, Green No. 3, Blue No. 1, etc., riboflavin, copper chlorofin sodium, titanium dioxide and the like. When a colorant is included, the content thereof is preferably 0.00001 to 3% by mass with respect to the entire composition.

  Examples of the brightener include waxes such as aluminum oxide, titanium oxide, mica titanium, shellac, carnauba wax, and candelilla wax, and calcium stearate. When a brightener is included, the content is preferably 0.01 to 5% by mass with respect to the entire composition.

  The pH of the composition of the present invention is preferably 6 to 9, and more preferably 6 to 8, from the viewpoints of effectiveness and stability. The pH may be adjusted using a pH adjuster as necessary. Examples of the pH adjuster include phosphoric acid or a salt thereof (sodium phosphate, sodium hydrogen phosphate, etc.), citric acid or a salt thereof (such as sodium citrate), malic acid or a salt thereof, gluconic acid or a salt thereof, maleic acid Or a salt thereof, succinic acid or a salt thereof, glutamic acid or a salt thereof, lactic acid, hydrochloric acid, acetic acid, nitric acid, sodium hydroxide, or potassium hydroxide.

  Examples of the solvent include water and lower alcohols having 3 or less carbon atoms such as ethanol and propanol. The amount of the solvent may be adjusted to an appropriate amount for each dosage form. For example, when the composition of the present invention is a toothpaste, the preferred solvent is water, and the water content relative to the total amount of the oral composition is preferably 10 to 90 mass%, more preferably 20 to 70 mass%. A part of the water can be substituted with a lower alcohol, and the amount of the lower alcohol is preferably 0 to 30% by mass, and more preferably 0 to 10% by mass with respect to the total amount of the toothpaste. Also, for example, when the composition of the present invention is a liquid oral composition such as a mouthwash or liquid dentifrice, the preferred solvent is water and / or lower alcohol, and the total amount of water and lower alcohol relative to the total amount of liquid oral composition is 30-95 mass% is preferable, and 40-90 mass% is more preferable.

  Examples of excipients include syrup, glucose, fructose, invert sugar, dextrin, oligosaccharide and the like. When the composition is a solid formulation, the composition typically includes an excipient. When an excipient is included, the content thereof may be appropriately determined within a range not impairing the effects of the present invention.

  Chewing gum is chewing elastic with a gum base and a saccharide as main ingredients, and may have a sugar coating as necessary. As a gum base mix | blended with a chewing gum main body, what is normally used for chewing gum is mentioned, for example. The gum base is, for example, a polyvinyl acetate resin (average polymerization degree of about 100 to about 1000), natural resins (ticule, gelton, solver, etc.), resins for gum base such as polyisobutylene, polybutene, ester gum (base agent), Emulsifier, calcium carbonate, calcium phosphate, filler (such as talc), lanolin, stearic acid, sodium stearate, potassium stearate, glyceryl triacetate, plasticizer or softener such as glycerin, natural wax, petroleum wax, paraffin, etc. The thing which mix | blended the component is mentioned. A commercially available product can be used as the gum base. Specifically, a gum base manufactured by Natural Base Co., Ltd. and a gum base manufactured by Youth Co., Ltd. are suitable. In addition, the said gum base may contain coloring agents, such as natural pigment | dyes, such as gardenia, safflower, and abalone, and titanium dioxide.

  The content of the gum base is usually 10 to 50% by mass and preferably 15 to 30% by mass with respect to the entire composition.

  Tablet confectionery is a saccharide-based material that is compression-molded with a device such as a tableting machine, and may have a sugar coating as required. The tablet confection can be produced by a conventional method, and is not particularly limited. For example, the confectionery can be produced by mixing each component and compressing it with an apparatus such as a tableting machine (for example, under a pressure condition of 5 to 20 kN). Good.

Examples of candy include soft candy such as caramel and nougat, and hard candy such as drop and toffee. Although not particularly limited, hard candy is preferable in terms of imparting a high functional feeling. The hard candy can be produced by a conventional method, and is not particularly limited. For example, water is added to raw materials other than the functional ingredient and the fragrance, and the mixture is boiled at a high temperature (eg, 140 to 200 ° C.) and then cooled (eg, 70 to 70 to Up to 130 ° C.), a functional component and a fragrance may be added, and further cooled and molded. In order to mix stably while maintaining the activity of the functional ingredient, water is added to raw materials other than the functional ingredient and the fragrance, and after boiling at a high temperature (140 to 200 ° C.), cooling (for example, from 70 ° C. to 100 ° C.) However, it is more preferable to manufacture by a method of adding a functional ingredient and a fragrance, further cooling and molding.
Silicic anhydride is preferred.

  EXAMPLES Hereinafter, although an Example is given and this invention is demonstrated further in detail, this invention is not limited to them.

Examples 1-14 and Comparative Examples 1-4
The main raw materials used in the examples and comparative examples are shown below:
Pyrrolidone carboxylic acid: “AJIDEW A-100 (registered trademark)” manufactured by Ajinomoto Co., Inc.
ε-aminocaproic acid: Ajinomoto Co., Inc. Tocopherol acetate: DSM Nutrition Japan Co., Ltd. “Tocopherol acetate”
Limonene: “Limonene” manufactured by Takasago International Corporation
Menthol: “Menthol JP” manufactured by Takasago International Corporation
Sorbit liquid (viscous agent), silicic anhydride (abrasive), propylene glycol (viscous agent), sodium carboxymethylcellulose (binder), sodium lauryl sulfate (surfactant), sodium saccharin (sweetener), fluoride Sodium (medicinal ingredient), sodium hydroxide (pH adjuster), fragrance (other than (C) ingredient), purified water (solvent)

Toothpastes having the compositions described in Tables 1 to 4 were prepared according to the following procedures (1) to (4).
(1) Pyrrolidonecarboxylic acid, ε-aminocaproic acid, fluorine compound (sodium fluoride, sodium monofluorophosphate), vitamin E, sodium saccharin, and 70% sorbite solution were mixed and dissolved at room temperature in purified water (phase A).
(2) Sodium carboxymethylcellulose was dispersed in propylene glycol at room temperature (phase B).
(3) B phase was added and mixed in the A phase under stirring to prepare C phase.
(4) In phase C, sodium lauryl sulfate and anhydrous silicic acid are mixed at room temperature using a kneader (manufactured by Ishiyama Kosakusho), and sodium hydroxide is added and mixed to adjust the pH, followed by reduced pressure ( Defoaming was performed at 5.3 kPa) to obtain a dentifrice composition.

● Evaluation method of anti-inflammatory effect Each sample was prepared using the rat carrageenin edema method shown below, which is a typical in vivo evaluation method as an anti-inflammatory effect determination method, using the dentifrice compositions prepared in Examples and Comparative Examples as samples. The anti-inflammatory effect of was evaluated.

-Rat carrageenan edema method-
The right hind limb volume (V0) before inflammation of 5-week-old female Wistar rats in good health was measured with an edema volume measuring device (TK101, “PLETYSMOMETER” manufactured by Unicom Corporation). The rat's head is covered with a licking prevention hood, and the right hind limb is immersed in a sample diluted 3-fold with water for 30 seconds, and 0.1 mL of a 1% by weight carrageenan solution is injected subcutaneously into the rat right hind limb sole for 5 hours. The right hind limb volume (V1) after (after inflammation) was measured. The edema inhibition rate was calculated according to the following formula, and the anti-inflammatory effect was evaluated based on the following evaluation criteria.

  In addition, 5 rats were used for each group of the drug-treated group and the drug-untreated group. In the drug-treated group, each dentifrice composition was orally administered before inflammation, and nothing was administered in the drug-untreated group.

(formula)
Edema suppression rate (%) = 100 − [(V1−V0) / (V1′−V0 ′)] × 100
V1: Edema volume of drug-treated group [right hind limb volume after inflammation]
V0: right hind limb volume before inflammation V1 ': edema volume of drug untreated group [right hind limb volume after inflammation]
V0 ′: Right hind limb volume before inflammation

·Evaluation criteria:
A: Edema inhibition rate is 60% or more B: Edema inhibition rate is 50% or more and less than 60% C: Edema inhibition rate is 40% or more and less than 50% D: Edema inhibition rate is less than 40%

● Method for evaluating discoloration stability For the dentifrice compositions prepared in the examples and comparative examples, the appearance immediately after production and the appearance after storage for 1 month in a 60 ° C. environment are visually confirmed, and the discoloration stability is based on the following evaluation criteria. Evaluated.

·Evaluation criteria:
5 points: No color change and no problem.
4 points: Deterioration of discoloration is slightly seen, but at a level that does not cause any problem.
3 points: Deterioration of discoloration is observed, but at a level that is not a problem.
Two points: Although there is no problem immediately after production, there is a problem that discoloration is remarkably deteriorated after storage for 1 month in a 60 ° C. environment.
1 point: Discoloration is remarkably worse immediately after production, causing a problem.

[Footnotes in Tables 1 to 4]
* 1 Use appropriate amount of sodium hydroxide (pH adjuster) to adjust the pH (20 ° C) of the dentifrice composition to 6.5-7.5.

From the results of Tables 1 to 4, the following can be understood. In Comparative Example 2 , since the component (B) was not included, no deterioration in discoloration stability due to the component (B) was observed, but naturally the anti-inflammatory effect was not exhibited. In Comparative Example 1 lacking the component (A), the anti-inflammatory effect of the component (B) was not exhibited. Further, Comparative Example 3 lacking the component (C) and Comparative Example 4 containing catechin instead of the component (C) had a problem in discoloration stability. On the other hand, in the examples containing the components (A) to (C), both the anti-inflammatory effect and the discoloration stability were good. This result shows that the composition for oral cavity of the present invention can exert an anti-inflammatory effect, and there is no problem with respect to discoloration stability.

Formulation Examples 1-4
Dentifrices were prepared according to the formulation shown in Table 5. All obtained dentifrices showed good anti-inflammatory effects and discoloration stability.

[Footnotes in Table 5]
* 1 Use appropriate amount of sodium hydroxide (pH adjuster) to adjust the pH (20 ° C) of the dentifrice composition to 6.5-7.5.

Claims (2)

(A) pyrrolidone carboxylic acid and / or salt thereof; (B) ε-aminocaproic acid and / or salt thereof; and (C) vitamin E and / or limonene, terpinolene, α-pinene, β-pinene, or caran. Or composition for oral cavity containing 2 or more . Vitamin E, tocopherols, tocotrienols, and on one or two or more of tocopherol acetate, oral composition of claim 1.